SCHEMBL3940262

SCHEMBL3940262

CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3[C@@H](O)C[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 11/20 1.00
LMNA P02545 3/20 1.00
NR3C1 P04150 5/20 0.80
SMN1; SMN2 Q16637 4/20 0.80
CYP2C19 P33261 3/20 0.80
HSD17B10 Q99714 3/20 0.80
SERPINA6 P08185 3/20 0.80
CYP3A4 P08684 3/20 0.80
MAPT P10636 3/20 0.80
PGR P06401 2/20 0.80
SHBG P04278 2/20 0.80
KMT2A Q03164 2/20 0.80
NFKB1 P19838 2/20 0.80
NR3C2 P08235 1/20 0.80
AR P10275 1/20 0.76
CHRM1 P11229 1/20 0.76
MEN1 O00255 1/20 0.71
ADORA3 P0DMS8 1/20 0.71
MAPK3 P27361 1/20 0.71
BLM P54132 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19327109 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL139280 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL13754708 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL139279 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL2507571 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL14523057 1.00 HIF1A (1.00) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL1626384 0.92 HIF1A (0.84) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL1626382 0.92 HIF1A (0.84) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL2484782 0.92 HIF1A (0.84) HIF1ALMNANR3C1SMN1; SMN2CYP2C19
SCHEMBL13147966 0.92 HIF1A (0.84) HIF1ALMNANR3C1SMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976997-B1 PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA,10ALPHA-STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS SOLVAY PHARM GMBH (DE) 2009-04-08 EP disclosed
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds SOLVAY PHARMACEUTICALS GMBH (DE) 2008-10-09 US disclosed
US-20070212751-A1 Microbial method for the 11beta hydroxylation of 9beta, 10alpha-steriods SOLVAY PHARMACEUTICALS GMBH (DE) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds HSD17B11, CYP19A1, ESRRA HIF1A 2433/4885LMNA 1111/4885NR3C1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.